Second schizophrenia treatment discovered at Vanderbilt’s Warren Center enters Phase I clinical trial

Written By Hannah Schaeffer
 

A new potential treatment for schizophrenia discovered through the Warren Center for Neuroscience Drug Discovery has entered Phase 1 clinical trials, marking the fifth WCNDD therapeutic to advance into human testing.

Read more here.

Hannah Schaeffer
Previous

Vanderbilt honors 2025 Master Innovators who drive breakthrough research and commercial impact
Next

Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-898